Ключевые слова
Как цитировать
Аннотация
Колоректальный рак (КРР) — гетерогенное заболевание с огромным количеством изменений на клеточном и молекулярном уровнях. Мутации в гене KRAS встречаются почти у каждого второго пациента с КРР и служат как прогностическим, так и предиктивным биомаркером. Отдельной прогностически неблагоприятной когортой являются пациенты с KRASG12C-позитивным мКРР, на долю которых приходится около 4 % всех случаев. В настоящее время сразу несколько ингибиторов, специфичных для аллеля KRASG12C, проходят III фазу клинических испытаний; кроме того, активно изучаются новые препараты и стратегии лечения. В этой статье мы приводим анализ современных подходов к лечению пациентов с KRAS-mut мКРР.
Библиографические ссылки
Martianov A.S., Mitiushkina N.V., Ershova A.N., et al. KRAS, NRAS, BRAF, HER2 and MSI status in a large consecutive series of colorectal carcinomas. Int J Mol Sci. 2023; 24(5): 4868.-DOI: 10.3390/ijms24054868.
Cremolini C., Antoniotti C., Stein A., et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020: JCO2001225.-DOI: 10.1200/JCO.20.01225.
Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11): 1023-34.-DOI: 10.1056/NEJMoa1305275.
Heinemann V., von Weikersthal L.F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10): 1065-75.-DOI: 10.1016/S1470-2045(14)70330-4.
Van Cutsem E., Yaeger R., Delord J.P., et al. Phase Ib/II Study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer. Oncologist. 2023; 28(12): e1209-e1218.-DOI: 10.1093/oncolo/oyad210.
Bennouna J., Sastre J., Arnold D., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1): 29-37.-DOI: 10.1016/S1470-2045(12)70477-1.
Fernández Montes A., Martínez Lago N., Covela Rúa M., et al J. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019; 8(3): 882-889.-DOI: 10.1002/cam4.1903.
Obermannová R., van Cutsem E., Yoshino T., et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016; 27(11): 2082-2090.-DOI: 10.1093/annonc/mdw402.
Федянин М.Ю. Современная клиническая и молекулярно-биологическая платформа лечения пациентов раком толстой кишки: дис. … д-ра мед. наук. М., 2018. 414 c. [Fedyanin M.Yu. Modern clinical and molecular biological platform for the treatment of patients with colon cancer: dis. ... Doctor of Medical Sciences, Moscow. 2018.;414 (In Rus)].
Osumi H., Takashima A., Ooki A., et al. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer. Transl Oncol. 2023; 35: 101718.-DOI: 10.1016/j.tranon.2023.101718.
Albuquerque J., Neto da Silva D., Padrão T., et al. Loss of RAS mutations in liquid biopsies of patients with multi-treated metastatic colorectal cancer. Oncologist. 2024; 29(3): e337-e344.-DOI: 10.1093/oncolo/oyad299.
Harada K., Yuki S., Kawamoto Y., et al. Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases. Ther Adv Med Oncol. 2023; 15: 17588359231216090.-DOI: 10.1177/17588359231216090.
Eng C., Kim T.W., Bendell J., et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019; 20(6): 849-861.-DOI: 10.1016/S1470-2045(19)30027-0.
Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 303-12.-DOI: 10.1016/S0140-6736(12)61900-X.
Li J., Qin S., Xu R., et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015; 16(6): 619-29.-DOI: 10.1016/S1470-2045(15)70156-7.
Mayer R.J., van Cutsem E., Falcone A., et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372(20): 1909-19.-DOI: 10.1056/NEJMoa141432.
van de Haar J., Ma X., Ooft S.N., et al. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nat Med. 2023; 29(3): 605-614.-DOI: 10.1038/s41591-023-02240-8.
Prager G.W., Taieb J., Fakih M., et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023; 388(18): 1657-1667.-DOI: 10.1056/NEJMoa2214963.
Tabernero J., Taieb J., Fakih M., et al. Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 2024; 9(3): 102945.-DOI: 10.1016/j.esmoop.2024.102945.
Basso M., Signorelli C., Calegari M.A., et al. Efficacy of regorafenib and trifluridine/tipiracil according to extended RAS evaluation in advanced metastatic colorectal cancer patients: a multicenter retrospective analysis. Target Oncol. 2024; 19(3): 371-382.-DOI: 10.1007/s11523-024-01050-3.
Nevala-Plagemann C., Sama S., Ying J., et al. A real-world comparison of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer in the United States. J Natl Compr Canc Netw. 2023; 21(3): 257-264.-DOI: 10.6004/jnccn.2022.7082.
Kim R., Tehfe M., Kavan P., et al. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D. Clin Colorectal Cancer. 2024; 23(2): 118-127.e6.-DOI: 10.1016/j.clcc.2024.03.001.
Edin S., Gylling B., Li X., et al. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer — possible implications for immunotherapy. Br J Cancer. 2024; 130(1): 143-150.-DOI: 10.1038/s41416-023-02483-9.
Damato A., Bergamo F., Antonuzzo L., et al. Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018). J Clin Oncol. 2022; 40: 16_suppl, 3509-3509.-DOI: 10.1200/JCO.2022.40.16_suppl.3509.
Lenz H.J., Parikh A., Spigel D.R., et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024; 12(3): e008409.-DOI: 10.1136/jitc-2023-008409.
Thibaudin M., Fumet J.D., Chibaudel B., et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nat Med. 2023; 29(8): 2087-2098.-DOI: 10.1038/s41591-023-02497-z.
Ostrem J.M., Peters U., Sos M.L., et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477): 548-51.-DOI: 10.1038/nature12796.
Yaeger R., Weiss J., Pelster M.S., et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023; 388(1): 44-54.-DOI: 10.1056/NEJMoa2212419.
Hong D.S., Fakih M.G., Strickler J.H., et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020; 383(13): 1207-1217.-DOI: 10.1056/NEJMoa1917239.
Sacher A., LoRusso P., Patel M.R., et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023; 389(8): 710-721.-DOI: 10.1056/NEJMoa2303810.
Kuboki Y., Fakih M., Strickler J., et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024; 30(1): 265-270.-DOI: 10.1038/s41591-023-02717-6.
Hong D.S., Kuboki Y., Strickler J.H., et al. Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy. J Clin Oncol. 2023; 41: 16_suppl, 3513-3513.-DOI: 10.1200/JCO.2023.41.16_suppl.3513.
Fakih M.G., Salvatore L., Esaki T., et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023; 389(23): 2125-2139.-DOI: 10.1056/NEJMoa2308795.
Desai J., Alonso G., Kim S.H., et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024; 30(1): 271-278.-DOI: 10.1038/s41591-023-02696-8.
Ran Z., Chen W., Shang J., et al. Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis. Gene. 2019; 721: 144097.-DOI: 10.1016/j.gene.2019.144097.
Ahn D.H., Barzi A, Ridinger M, et al. Onvansertib in combination with FOLFIRI and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a phase Ib clinical study. Clin Cancer Res. 2024; 30(10): 2039-2047.-DOI: 10.1158/1078-0432.CCR-23-3053.
Li J., Qin S., Xu R.H., et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial. JAMA. 2018; 319(24): 2486-2496.-DOI: 10.1001/jama.2018.7855.
Dasari A., Lonardi S., Garcia-Carbonero R., et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023; 402(10395): 41-53.-DOI: 10.1016/S0140-6736(23)00772-9.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2025